DLBCL

Dr S
Videos
Dr Shah Highlights a First in-Human Study of YTB323 for Patients With R/R DLBCL
02/11/2022
Nirav Shah, MD, highlights a first in-human study of YTB323 for the treatment of patients with R/R DLBCL, presented at ASH 2021.
Nirav Shah, MD, highlights a first in-human study of YTB323 for the treatment of patients with R/R DLBCL, presented at ASH 2021.
Nirav Shah, MD, highlights a...
02/11/2022
Oncology
idea
Test Your Knowledge
Quiz: SWOG Trials Highlight Extranodal Presentation in Limited Stage DLBCL
12/22/2021
Fill in the blank: Patients with LS DLBCL treated on 3 SWOG studies had ______ PFS and OS, regardless of extranodal versus nodal presentation.
Fill in the blank: Patients with LS DLBCL treated on 3 SWOG studies had ______ PFS and OS, regardless of extranodal versus nodal presentation.
Fill in the blank: Patients with...
12/22/2021
Oncology
News
Naratuximab Emtansine Plus Rituximab Shows Safety in Patients With DLBCL and Other B-NHLs
12/08/2021
A phase 2 study of naratuximab emtansine plus rituximab found it has promising safety and efficacy for patients with DLBCL and other B-NHLs; these data were presented at the 2021 Annual ASH Meeting.
A phase 2 study of naratuximab emtansine plus rituximab found it has promising safety and efficacy for patients with DLBCL and other B-NHLs; these data were presented at the 2021 Annual ASH Meeting.
A phase 2 study of naratuximab...
12/08/2021
Oncology
writing
Test Your Knowledge
Quiz: Is This Acalabrutinib Combo Safe for Patients With R/R DLBCL?
11/15/2021
True or false: Acalabrutinib plus AXD9150 is safe and tolerable for patients with R/R DLBCL, but has limited efficacy.
True or false: Acalabrutinib plus AXD9150 is safe and tolerable for patients with R/R DLBCL, but has limited efficacy.
True or false: Acalabrutinib...
11/15/2021
Oncology
News
BTK, STAT3 Targeting Is Safe in R/R DLBCL, But Has Limited Efficacy
11/15/2021
A phase 1b study found acalabrutinib, plus AZD9150 is safe and tolerable for patients with R/R DLBCL, but has limited efficacy; these findings were presented at the 2021 ASH Annual Meeting.
A phase 1b study found acalabrutinib, plus AZD9150 is safe and tolerable for patients with R/R DLBCL, but has limited efficacy; these findings were presented at the 2021 ASH Annual Meeting.
A phase 1b study found...
11/15/2021
Oncology
qqq
Test Your Knowledge
Quiz: Does Tafasitamab Show Tolerability in DLBCL?
11/11/2021
True or false: Tafasitamab with or without lenalidomide and R-CHOP are both tolerable regimens for patients with DLBCL.
True or false: Tafasitamab with or without lenalidomide and R-CHOP are both tolerable regimens for patients with DLBCL.
True or false: Tafasitamab with...
11/11/2021
Oncology
Conference Insider
Tafasitamab With or Without Lenalidomide and R-CHOP Tolerable for Patients With DLBCL
11/11/2021
A phase 1B study shared at the 2021 Annual ASH Meeting reported on the safety and tolerability of tafasitamab in newly diagnosed DLBCL.
A phase 1B study shared at the 2021 Annual ASH Meeting reported on the safety and tolerability of tafasitamab in newly diagnosed DLBCL.
A phase 1B study shared at the...
11/11/2021
Oncology
qq
Test Your Knowledge
Quiz: What Combo Regimen Shows a Promising Safety Profile in DLBCL?
11/09/2021
Which of the following combinations showed a promising safety profile in patients with DLBCL and other B-NHLs?
Which of the following combinations showed a promising safety profile in patients with DLBCL and other B-NHLs?
Which of the following...
11/09/2021
Oncology
qq
Test Your Knowledge
Quiz: Is Glofitamab Plus R-CHOP Tolerable for Patients With NHL, DLBCL?
11/08/2021
True or false: Glofitamab plus R-CHOP has tolerable safety in R/R NHL and previously untreated DLBCL?
True or false: Glofitamab plus R-CHOP has tolerable safety in R/R NHL and previously untreated DLBCL?
True or false: Glofitamab plus...
11/08/2021
Oncology
News
Glofitamab Plus R-CHOP Induces High Response Rates in NHL, DLBCL
11/08/2021
Findings from a phase 1b study found glofitamab plus R-CHOP induces high response rates with minimal CRS in patients with R/R NHL and previously untreated DLBCL. These data were presented at the 2021 ASH Annual Meeting.
Findings from a phase 1b study found glofitamab plus R-CHOP induces high response rates with minimal CRS in patients with R/R NHL and previously untreated DLBCL. These data were presented at the 2021 ASH Annual Meeting.
Findings from a phase 1b study...
11/08/2021
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use